5/2/2023 0 Comments Aperture 3 trial download"Our ability to predict patient outcome using TILs is strengthened when we combine it with tumor budding," Dr. Tumor-infiltrating lymphocytes (TILs) are a type of immune cell that has moved from the blood into a tumor and can recognize and kill cancer cells, and their density reflects the patient's anti-tumor immune response. Sinicrope and his colleagues were able to demonstrate that the density of tumor-infiltrating lymphocytes is a robust predictor of survival in patients with stage III colon cancer. Using colon cancer tissues from a completed clinical trial, Dr. The findings were published in the journal Annals of Oncology. Sinicrope, M.D., a gastroenterologist and oncologist at Mayo Clinic in Rochester, Minnesota. The findings are the result of research conducted by a group of investigators led by Frank A. The density of tumor-infiltrating lymphocytes when combined with an analysis of tumor budding may serve as a method to more accurately predict survival in patients with stage III colon cancer. Study findings show that using routine tissue sections could help guide recommendations for chemotherapy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |